Ziopharm Oncology (ZIOP) Tops Q4 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Ziopharm Oncology (ZIOP) Tops Q4 EPS by 5c

ZIOPHARM Reports Fourth-Quarter and Full-Year 2014 Financial Results and Recent Activities

February 26, 2015 5:10 PM EST

BOSTON, Feb. 26, 2015 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) today announced financial results for the fourth quarter and full year ended December 31, 2014, and provided an update on the company's recent activities.

"ZIOPHARM has achieved remarkable progress in the last several quarters, uniting a number of technologies and development know-how to deliver a truly one-of-a-kind immuno-oncology platform with transformative potential in the treatment of cancer," said Jonathan Lewis, M.D., Ph.D., chief executive officer of ZIOPHARM. "Bringing together RheoSwitch® technology with non-viral adoptive cell therapies, including CAR T, TCR and NK... More